DSM Announces Settlement Of Federal Class Antitrust Litigation

A class of businesses that purchased ethylene proplylene diene monomer (EPDM) between 1997 and 2001 has reached agreement with two subsidiaries of Royal DSM to settle a long-running antitrust dispute before trial in return for a payment of $25 million.

The EPDM class action, pending in the U.S. District Court for the District of Connecticut, was vigorously litigated by both sides; the DSM defendants consistently denied any wrongdoing in connection with the allegations. In 2006, competition enforcement authorities in the EU, U.S. and Canada concluded their EPDM investigations without bringing any charges against DSM or any of its employees. The DSM defendants have now entered into the settlement to eliminate the burden, expense and risk of further litigation. The proposed class action settlement is subject to Court approval.

If approved, and following due notice to the class members, the class action will be dismissed with prejudice and all claims asserted in the class action against the DSM defendants will be released.

 

Company

Royal DSM N.V.


6401 JH Heerlen

Company contact







Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.